Connect with us

Technology

Genea Biomedx and Gattaca Genomics Partner to Advance IVF Success Rates Through Groundbreaking Institutional Review Board Study

Published

on

This collaboration supports a landmark IRB-approved study integrating Genea Biomedx’s cutting-edge time-lapse imaging technology with Gattaca Genomics’ genetic testing expertise.

FT. LAUDERDALE, Fla., Oct. 9, 2024 /PRNewswire-PRWeb/ — Genea Biomedx, a global leader in assisted reproductive technology (ART), and Gattaca Genomics, a trailblazer in reproductive health offering cutting-edge genetic testing to empower patients in their family planning journey, are excited to announce a new partnership aimed at advancing success rates for in vitro fertilization (IVF). This collaboration supports a landmark Institutional Review Board-approved study integrating Genea Biomedx’s cutting-edge time-lapse imaging technology with Gattaca Genomics’ genetic testing expertise. Together, the two companies will apply learned insight that will significantly improve embryo selection in IVF and enhance clinical outcomes for patients worldwide.

“This study could be a game-changer for couples struggling with infertility. By combining time-lapse imaging and genetic testing, we aim to provide experts with the insights to identify the most viable embryos, making IVF more successful.”

As part of the Agreement, Genea Biomedx will provide exclusively its state-of-the-art Geri® time-lapse incubators to select IVF clinics participating in the study. These incubators allow for continuous, real-time monitoring of embryo development, ensuring optimal culture conditions and gathering invaluable data. This innovative approach is designed to deepen the understanding of how embryo development correlates with aneuploidy—a genetic condition caused by an abnormal number of chromosomes that can impact embryo viability.

The study, titled “Embryo Assessment Utilizing Time-lapse Imaging in Conjunction With Preimplantation Genetic Testing for Aneuploidy With Next-Generation Sequencing,” will integrate Geri’s high-resolution imaging with Gattaca Genomics’ leading-edge genetic testing solutions. By combining their strengths, the companies aim to develop a comprehensive dataset that may redefine how healthy embryos are selected, potentially transforming IVF success rates and clinical outcomes.

Unlocking Clinical Potential in Clinics Globally

This partnership strengthens the scientific foundation of IVF treatments and highlights the substantial potential for Genea Biomedx and Gattaca Genomics. The collaboration opens new opportunities in the growing IVF market by uniting Genea Biomedx’s technological innovations with Gattaca Genomics’ genetic expertise. Around 100 IVF clinics globally will benefit from access to integrated solutions that can improve patient success rates and clinical efficiencies, further driving demand for Geri incubators and advanced genetic testing.

“This collaboration represents an exciting step forward in the science and business of IVF,” said Marian Garriga, CEO of Genea Biomedx. “By joining forces, we provide fertility specialists with the advanced tools they need while tapping into a substantial market with potential for exponential growth.”

Dr. Mari Mitrani, Chief Scientific Officer and co-founder at Gattaca Genomics, added: “This study could be a game-changer for couples struggling with infertility. By combining time-lapse imaging and genetic testing, we aim to provide experts with the insights to identify the most viable embryos, making IVF more successful.”

A Global Opportunity for IVF Clinics

Genea Biomedx and Gattaca Genomics are inviting leading IVF clinics worldwide to participate in this groundbreaking study. Clinics that join the study will gain access to Geri time-lapse incubators and advanced genetic testing, contributing to a global dataset that will redefine embryo selection standards.

“This collaborative effort unites leading IVF clinics worldwide in a shared mission to improve patient care and success rates,” said Dr. Tyl Taylor, Director of Genetic Services at Gattaca Genomics. “By providing the Geri incubator, Genea Biomedx is enabling us to collect high-quality data on embryo development and aneuploidy, helping us unlock valuable insights that will benefit countless families on their fertility journeys.”

For more details about the study design and participation, please visit ClinicalTrials.gov.

About Genea Biomedx

Genea Biomedx is a leading global provider and manufacturer of medical devices designed to simplify and automate the fertility treatment process, focusing on improving clinical outcomes. Genea Biomedx’s team of experts is dedicated to reducing the impact of uncontrollable variables like human error and environmental factors through innovative technology that enhances industry standards. Our cutting-edge devices provide exceptional performance and reliability, ensuring optimal clinical outcomes. Our products increase efficiency and reduce errors with intuitive interfaces and automated features. We invest heavily in R&D to help revolutionize the IVF industry. Genea Biomedx is a trusted partner that provides exceptional customer service, training, and technical support to laboratories worldwide.

About Gattaca Genomics

Gattaca Genomics is a trailblazer in reproductive health, offering cutting-edge genetic testing to empower patients in their family planning journey. Our expertise in Preimplantation Genetic Testing (PGT) and Whole Genome Sequencing (WGS) provides crucial insights to inform meaningful decisions. Led by CEO Michael Carbonara and Chief Scientific Officer Dr. Maria Ines “Mari” Mitrani, our team combines visionary leadership with scientific rigor to deliver personalized support and a deep understanding of each family’s unique needs. Gattaca Genomics is transforming family planning by harnessing the power of advanced technology, offering sophisticated solutions that enhance the chances of a healthy pregnancy while minimizing genetic risks.

Media Contact

Melany Velasquez, Gattaca Genomics, 1 888-372-8679, marley@dontbealittlepitch.com, www.gattacagenomics.com

View original content:https://www.prweb.com/releases/genea-biomedx-and-gattaca-genomics-partner-to-advance-ivf-success-rates-through-groundbreaking-institutional-review-board-study-302271820.html

SOURCE Gattaca Genomics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Capital Advantage, Inc. Offers Tailored Financial Services for Kaiser Permanente® and TPMG Employees

Published

on

By

WALNUT CREEK, Calif., Jan. 10, 2025 /PRNewswire/ — Capital Advantage, Inc., a trusted name in wealth management, is proud to highlight its specialized services designed to meet the unique financial needs of Kaiser Permanente® and The Permanente Medical Group (TPMG) employees.

At Capital Advantage, we understand the complexities of Kaiser Permanente® and TPMG benefit plans. Our team is dedicated to helping healthcare professionals navigate their robust and often intricate benefit options. With over 30 years of expertise and a deep understanding of Kaiser’s offerings, we craft personalized financial plans to help maximize the value of our clients’ benefits.

“We recognize the unique challenges and opportunities that healthcare professionals face in managing their financial lives,” says Ian Castille, CFP®, Principal and Senior Financial Advisor at Capital Advantage, Inc.

Donna Zinman, CRPC®, Principal and Senior Advisor, adds, “Our goal is to educate our clients about their attractive benefit options and help them make the most of these opportunities.”

Key services for Kaiser Permanente® and TPMG employees include customized portfolio strategies and personalized guidance on retirement savings plans, identification of ideal pension options and annual open-enrollment benefit selections, advice on traditional vs. Roth 401(k) options, advanced tax-saving strategies (such as mega-backdoor Roth contributions), and simplification of retirement planning by working directly with Kaiser/TPMG’s benefits department. These services are designed to provide Kaiser/TPMG employees with peace of mind, confidence, and financial empowerment as they navigate their retirement and benefits planning.

About Capital Advantage, Inc.

Capital Advantage is a trusted, independently owned wealth management firm with over 40 years of experience helping individuals and families to achieve their financial goals. As a 100% fee-only fiduciary, Capital Advantage strives to provide financial peace of mind to each and every client, delivering large institution expertise with the personalized care and attention of a boutique firm. Our experienced advisors work closely with pre-retirees and retirees, women navigating unique financial journeys, and Kaiser Permanente® and The Permanente Medical Group (TPMG) employees to create strategies that provide clarity, confidence, and long-term success.

For more information on Capital Advantage’s services visit: Kaiser/TPMG Employees – Capital Advantage, Inc. or call (925) 299-1500 to contact one of our advisors for a no-cost initial consultation.

Disclaimer: Capital Advantage, Inc. is not affiliated, associated, authorized, endorsed by, or in any way officially connected with Kaiser Permanente® or TPMG (The Permanente Medical Group)

Limitations: No amount of experience, recognition, or past success, nor the achievement of any professional designation, certification, degree, or license should be construed by a client or prospective client as a guarantee that he/she will experience a certain level of results if Capital Advantage is engaged, or continues to be engaged, to provide investment advisory services. Please see Important Disclosure.

View original content to download multimedia:https://www.prnewswire.com/news-releases/capital-advantage-inc-offers-tailored-financial-services-for-kaiser-permanente-and-tpmg-employees-302348316.html

SOURCE Capital Advantage, Inc.

Continue Reading

Technology

NASA Sets Coverage for Firefly First Commercial Robotic Moon Launch

Published

on

By

WASHINGTON, Jan. 10, 2025 /PRNewswire/ — Carrying NASA science and technology to the Moon as part of the agency’s CLPS (Commercial Lunar Payload Services) initiative and Artemis campaign, Firefly Aerospace’s Blue Ghost Mission 1 is targeting launch Wednesday, Jan. 15. The mission will lift off on a SpaceX’s Falcon 9 rocket from Launch Complex 39A at the agency’s Kennedy Space Center in Florida.

Live launch coverage will air on NASA+ with prelaunch events starting Monday, Jan. 13. Learn how to watch NASA content through a variety of platforms, including social media. Follow all events at:

https://www.nasa.gov/live/

After the launch, Firefly’s Blue Ghost lander will spend approximately 45 days in transit to the Moon before landing on the lunar surface in early March. The lander will carry 10 NASA science investigations to further our understanding of the Moon’s environment and help prepare for future human missions to the lunar surface, as part of the agency’s Moon to Mars exploration approach. 

Science investigations on this flight aim to test and demonstrate lunar subsurface drilling technology, regolith sample collection capabilities, global navigation satellite system abilities, radiation tolerant computing, and lunar dust mitigation methods. The data captured could benefit humans on Earth by providing insights into how space weather and other cosmic forces impact Earth. 

The deadline has passed for media accreditation for in-person coverage of this launch. The agency’s media accreditation policy is available online. More information about media accreditation is available by emailing: ksc-media-accreditat@mail.nasa.gov.

Full coverage of this mission is as follows (all times Eastern):

Monday, Jan. 13
2:30 p.m. – Lunar science media teleconference with the following participants:

Chris Culbert, CLPS program manager, NASA’s Johnson Space CenterMaria Banks, CLPS project scientist, NASA Johnson

Audio of the teleconference will stream live on the agency’s website:

https://www.nasa.gov/live/

Media may ask questions via phone only. For the dial-in number and passcode, please contact the Kennedy newsroom no later than 1:30 p.m. EST Jan. 13, at: ksc-newsroom@mail.nasa.gov.

Tuesday, Jan. 14
1 p.m. – Lunar delivery readiness media teleconference with the following participants:

Nicola Fox, associate administrator, Science Mission Directorate at NASA HeadquartersJason Kim, CEO, Firefly AerospaceJulianna Scheiman, director, NASA science missions, SpaceXMark Burger, launch weather officer, Cape Canaveral Space Force Station’s 45th Weather Squadron

Audio of the teleconference will stream live on the agency’s website:

https://www.nasa.gov/live/

Media may ask questions via phone only. For the dial-in number and passcode, please contact the Kennedy newsroom no later than 12 p.m. EST on Tuesday, Jan. 14, at: ksc-newsroom@mail.nasa.gov.

Wednesday, Jan. 15
12:30 a.m. – Launch coverage begins on NASA+ and the agency’s website.

1:11 a.m. – Launch

NASA Launch Coverage
Audio only of the media teleconferences and launch coverage will be carried on the NASA “V” circuits, which may be accessed by dialing 321-867-1220, -1240, or -7135. On launch day, the full mission broadcast can be heard on -1220 and -1240, while the countdown net only can be heard on -7135 beginning approximately one hour before the mission broadcast begins.

On launch day, a “tech feed” of the launch without NASA TV commentary will be carried on the NASA TV media channel.

NASA Website Launch Coverage
Launch day coverage of the mission will be available on the NASA website. Coverage will include live streaming and blog updates beginning no earlier than 12:30 a.m. EST Jan. 15, as the countdown milestones occur. On-demand streaming video and photos of the launch will be available shortly after liftoff. For questions about countdown coverage, contact the Kennedy newsroom at 321-867-2468. Follow countdown coverage on our launch blog for updates.

NASA Virtual Guests for Launch
Members of the public can register to attend this launch virtually. Registrants will receive mission updates and activities by email, including curated mission resources, schedule updates, and a virtual guest passport stamp following a successful launch. Print your passport and get ready to add your stamp!

Watch, Engage on Social Media
Let people know you’re following the mission on X, Facebook, and Instagram by using the hashtag #Artemis. You can also stay connected by following and tagging these accounts:

X: @NASA, @NASAKennedy, @NASAArtemis, @NASAMoon

Facebook: NASA, NASAKennedy, NASAArtemis

Instagram: @NASA, @NASAKennedy, @NASAArtemis

Coverage en Español
Did you know NASA has a Spanish section called NASA en español? Check out NASA en español on X, Instagram, Facebook, and YouTube for additional mission coverage.

Para obtener información sobre cobertura en español en el Centro Espacial Kennedy o si desea solicitar entrevistas en español, comuníquese con Antonia Jaramillo o Messod Bendayan a: antonia.jaramillobotero@nasa.gov o messod.c.bendayan@nasa.gov.

For media inquiries relating to the launch provider, please contact SpaceX’s communications department by emailing: media@spacex.com. For media inquiries relating to the CLPS provider, Firefly Aerospace, please contact Firefly’s communication department by emailing: press@fireflyspace.com.
For more information about the agency’s CLPS initiative, see:

https://www.nasa.gov/clps

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nasa-sets-coverage-for-firefly-first-commercial-robotic-moon-launch-302348344.html

SOURCE NASA

Continue Reading

Technology

Universal Brain Announces Publication of Groundbreaking Depression Research Using Multiple Event-Related Potentials

Published

on

By

New findings support the company’s neuroscience-driven approach to precision psychiatry, offering actionable insights for personalized depression treatment

PALO ALTO, Calif., Jan. 10, 2025 /PRNewswire/ — Universal Brain, a pioneering technology company focused on transforming mental healthcare through neuroscience, today announced the publication of its latest peer-reviewed study, “Neurotyping depression using multiple event-related potentials (ERPs): Leveraging task-based variation to predict remission in depression,” the paper introduces a novel framework for detecting unique neurophysiological patterns that can help predict which depressed patients are most likely to achieve remission from depression.

“By combining several EEG paradigms with novel statistical analyses, we’re moving closer to a future where depression therapies can be precisely tailored to each individual,” said Kazu Okuda, Chief Executive Officer of Universal Brain. “In particular, we are poised to leverage a battery of EEG paradigms to better subtype depression – which will pave the way for more precision in treatment development and selection.  These functional measures of brain activity (i.e., neurotypes) will be used to determine what treatment works best for whom.”

Key Highlights of the Study

Multi-Task ERP Analyses
The study leveraged multiple cognitive and emotional tasks to capture a broader spectrum of brain responses, thereby enabling more robust classification of distinct depression subtypes.Predictive Neurotyping
Through comprehensive ERP assessment, researchers identified patterns linked to a higher likelihood of remission in depression, paving the way for more targeted clinical strategies. Combining ERPs from multiple tasks outperformed classifications based on more traditional single-task analyses.Implications for Precision Psychiatry
These findings underscore the potential of individualized treatment pathways—an approach backed by emerging research in the field of precision psychiatry, which calls for data-driven, personalized solutions to improve outcomes in mental health.

“This work is especially exciting because it bridges the gap between laboratory-based assessments and potential real-world clinical practice. We believe our new method can help physicians potentially select treatment but also help clinicians fine-tune therapeutic interventions to an individual’s unique neural signature,” commented Greg Hajcak, Chief Scientific Advisor of Universal Brain. “By leveraging multiple ERPs in varying tasks, we can aim to better predict who will respond to specific treatments, a key step in transforming how we approach depression management.”

Championing Precision Psychiatry

Universal Brain’s overarching mission is to integrate cutting-edge neuroscience with clinical insights to advance precision psychiatry—a transformative model of care that personalizes interventions based on individual biological, behavioral, and environmental factors. This focus resonates with emerging trends in psychiatric research to enhance treatment outcomes.

In close collaboration with academic institutions, research hospitals, and clinical partners, Universal Brain continues to drive neuroscience-based innovation that bridges the gap between academic discoveries and real-world patient care.

For more information on Universal Brain’s research and the company’s commitment to developing neuroscience-driven solutions for mental health, please visit universal-brain.com or email us at media@universal-brain.com.

About Universal Brain

Universal Brain is a science-driven technology company dedicated to revolutionizing mental healthcare by unlocking the power of precision psychiatry. Drawing on advances in neuroscience, data analytics, and engineering, Universal Brain develops innovative tools and platforms that personalize psychiatric treatment and improve patient outcomes. To learn more, visit www.universal-brain.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/universal-brain-announces-publication-of-groundbreaking-depression-research-using-multiple-event-related-potentials-302348351.html

SOURCE Universal Brain

Continue Reading

Trending